A new way to deliver treatment for eye inflammation
DECON: A sustained topical delivery platform to treat ocular inflammation
This study is working on a new eye treatment that can help kids and teens with eye infections and inflammation, making it easier for them to manage their condition by needing to use the medicine less often.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11094875 on NIH RePORTER |
What this research studies
This research focuses on developing a sustained topical delivery system to treat ocular inflammation, which is a leading cause of blindness. The approach aims to improve patient compliance by reducing the frequency of medication administration, particularly for conditions like ocular herpes that affect children and adolescents. By combining antimicrobial and anti-inflammatory treatments, the research seeks to provide a more effective and convenient option for managing eye infections and inflammation. Patients will receive a topical treatment that can help control both the infection and the resulting inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adolescents experiencing ocular herpes or other forms of ocular inflammation.
Not a fit: Patients with non-inflammatory eye conditions or those who do not respond to topical treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and easier-to-use treatments for patients suffering from ocular inflammation, potentially reducing the risk of blindness.
How similar studies have performed: Previous research has shown promise in developing sustained delivery systems for other conditions, suggesting potential success for this novel approach in ocular treatment.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Yadavalli, Tejabhiram — University of Illinois at Chicago
- Study coordinator: Yadavalli, Tejabhiram
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.